Objective: Analgesic

anti-inflammatory and anti-ulcer were choosed as pharmacological targets to evaluate the pharmacodynamics of Yulian Cataplasm therefore to provide the experimental basis for clinical applications of the cataplasm. Method: The rat experimental gastric ulcer was established by using pyloric ligation. Rat paw edema was caused by inflammation action of carragenan. The mouse model of analgesia was established by the method of somatic wrenching. The effects of Yulian Cataptosm(rats 12

6

3 g ·kg-1

mice 6

3

1.5 g ·kg-1

ig)were evaluated by ulcer index

inhibition rate and the incidence of ulcers

foot swelling

writhing and capillary permeability. Yulian cataplasm of high

middle and low dose groups were used respectively. Result: The external Yulian Cataplasm lowered ulcer index in a dose dependent manner. only the high and middle dose groups could increase excretion of pepsin while reduced the incidence of ulcers. Both middle and low dose groups could reduce rat paw swelling

middle dose group lasted longer duration of action. High and middle dose groups could decrease capillary permeability

all the three dose groups could reduce the writhing

and compared with excipient group

there was significant difference (P<0.05

P<0.01). Conclusion: Yulian Cataplasm could obviously inhibite the gastric ulcer

pain and swelling with the role of anti-inflammatory

it also provided an experimental basis on the feasibility of treating gastrointestinal diseases with transdermal drug delivery.